NCT03777215CompletedEarly phase 1
Angiotensin-(1-7) and Energy Expenditure in Human Obesity
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
The objective of this study is to better define the role of the hormone angiotensin-(1-7) in energy balance. We will test the overall hypothesis that angiotensin-(1-7) increases resting energy expenditure and promotes markers of heat production (thermogenesis) in white adipose tissue in human obesity.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- First submitted
- 12 Dec 2018
- Start date
- 26 Sept 2019
- Primary completion date
- 15 Apr 2026
- Lead sponsor
- Amy Arnold
- Diseases
- Obesity
- NCT number
- NCT03777215
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 27
- From 26 Sept 2019 to the primary completion date, 15 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Alcohol or drug abuse
- Treatment with anticoagulants (e.g. warfarin)
- Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month)
- Treatment with medications influencing energy expenditure (e.g. psychostimulants)
- Treatment with any investigational drug in the 1-month preceding the study
Other illness
- Decisional impairment
- History of serious cardiovascular disease other than hypertension (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack).
- History or presence of immunological or hematological disorders
Lab values
- Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
- Impaired renal function (serum creatinine \>2.0 mg/dl)
Age
- Age ≤ 17 or ≥ 61 years
Other
- Pregnant, nursing, or postmenopausal women
- Prisoners
- Current smokers
- Highly trained athletes
- Claustrophobia
- Subjects with \>5% weight change in the past 3 months
- Impaired hepatic function (aspartate aminotransferase or alanine aminotransferase levels \>2 times upper limit of normal range)
- Anemia
- Inability to give, or withdraw, informed consent
Who the study is looking for
- Men and women of all races
- Capable of giving informed consent
- Age 18-60 years
- Body mass index (BMI) between 30-40 kg/m2
- Satisfactory history and physical exam
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Penn State Milton S. Hershey Medical Center Coordinator of this site? Confirm its status | Hershey | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.